Two Potential Biomarkers for the Diagnosis and Prognosis of Laryngeal Carcinoma: CCL20 and IL-17A

Yaoshu Teng,1 Hanyi He,1 Hongmei Wang,2 Yueyue Lu,3 Xinlu Wang,3 Yong Li,1 and Zhihong Lin4

1Department of Otorhinolaryngology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
2Department of Otorhinolaryngology, Chaoyang Central Hospital, Chaoyang 122000, China
3The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310006, China
4Department of Otorhinolaryngology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310008, China

Correspondence should be addressed to Yaoshu Teng; yaoshu_teng@stu.cpu.edu.cn

Received 6 February 2022; Accepted 10 March 2022; Published 4 April 2022

This study is to uncover the possibilities of CCL20 and IL-17A to be potential hallmarks for laryngeal carcinoma. Relative levels of CCL20 and IL-17A in laryngeal carcinoma tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Correlation between CCL20 and IL-17A was analyzed by Pearson correlation test. Receiver operating characteristic (ROC) curves were depicted for assessing diagnostic values of CCL20 and IL-17A in laryngeal carcinoma. In addition, 98 laryngeal carcinoma patients were followed up for 5 years. Their follow-up data were utilized for assessing prognostic values of CCL20 and IL-17A. CCL20 and IL-17A were upregulated in laryngeal carcinoma tissues, which are unfavorable factors for the prognosis of laryngeal carcinoma. CCL20 and IL-17A are promising hallmarks of laryngeal carcinoma.

1. Introduction

Laryngeal carcinoma is one of the highly invasive malignant tumors originating from head and neck, accounting for 2.4% of malignant tumors annually [1]. Unhealthy lifestyle, external environment, genetic factors, and HPV (human papillomavirus) infection are all risk factors for laryngeal carcinoma [2]. Great strides have been made on surgical procedures, chemotherapy, and radiotherapy for laryngeal carcinoma. However, detective rate of early-stage laryngeal carcinoma is low because of insidious symptoms [3, 4]. It is necessary and urgent to search for effective hallmarks for diagnosing laryngeal carcinoma as early as possible.

CCL20 is a newly discovered chemokine belonging to the CC subfamily. The primary structure of its mature body has two forms, which can participate in the directed migratory process of immune cells by binding to corresponding receptors. CCL20 is of significance in the development of autoimmune diseases, tumors, infectious diseases, and inflammatory diseases [5]. A relevant study has confirmed the accelerative effects of CCL20 on proliferative and migratory abilities in human pancreatic cancer cell line COLO-357 [6]. Lu et al. [7] have shown that CCL20 can promote the progression of laryngeal carcinoma.

IL-17 cytokine family contains six members, namely, IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. IL-17A (also known as IL-17) is the most representative member of the IL-17 family [8]. IL-17A is mainly secreted by T helper cell 17 and, sometimes, neutrophils, eosinophils, and mononuclear macrophages [9–11]. Yang et al. [12] and Xiang et al.
have shown that IL-17RA, the IL-17A receptor, is expressed in both cancer stem cells and cancer tissues. Exogenous IL-17A and IL-17A in cancer cells directly stimulate proliferation ability in cancer [14]. It is reported that IL-17A is upregulated in laryngeal carcinoma [15]. In colorectal cancer, CCL20 and IL-17 are synergistically utilized as biological hallmarks for diagnosing and predicting the prognosis of colorectal cancer [16]. In this paper, we mainly explore the diagnostic and prognostic potentials of CCL20 and IL-17A in laryngeal carcinoma. Our findings provide new directions in therapeutic strategies of laryngeal carcinoma.

2. Materials and Methods

2.1. Sample Collection. Laryngeal carcinoma tissues and normal ones were collected from 98 laryngeal carcinoma patients admitted in the Department of Otorhinolaryngology and Head and Neck Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, and Chaoyang Central Hospital, from April 2016 to December 2018. Follow-up data of every enrolled subject were collected. Patients and their families in this study have been fully informed. This study was approved by the Ethics Committee of Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine.

2.2. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). TRIzol (Invitrogen, Carlsbad, CA, USA) was utilized for isolating RNA from laryngeal tissues. RNA was reversely transcribed into complementary deoxyribose nucleic acid (cDNA) using PrimeScript RT Reagent (TaKaRa, Otsu, Japan) and applied for qRT-PCR. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was the internal reference. Primer sequences were as follows: CCL20 forward: 5′-AGCAGCAAGCAACTACGACT-3′, reverse: 5′-TCTTAGGCTGAGGAGGTTCA-3′; IL-17A forward: 5′-TCCCACGAAATCCAGGATGC-3′, reverse: 5′-GGATGTTCAAGGATGC-3′; GAPDH forward: 5′-TGAA GTTGGAGTGACCG-3′, reverse: 5′-CCTGGAAGATG GTGATGGC-3′.

2.3. Follow-Up. Postoperative follow-up was conducted in every laryngeal carcinoma patient by clinical review or telephone once every three months in the first year and once every six months till 2018 year. Death of patient was the end point of follow-up.

2.4. Statistical Analysis. Statistical Product and Service Solutions (SPSS) 22.0 (IBM, Armonk, NY, USA) was used for data analyses. Differences between two groups were compared by the t-test. Correlation between CCL20 and IL-17A was analyzed by the Pearson correlation test. Diagnostic potentials of CCL20 and IL-17A were assessed by depicting receiver operating characteristic (ROC) curves. Their prognostic values were evaluated by the Kaplan-Meier method, followed by log-rank test for comparing differences between two curves. P < 0.05 was considered as statistically significant.

3. Results

3.1. Upregulation of CCL20 and IL-17A in Laryngeal Carcinoma. Compared with normal tissues, CCL20 and IL-17A were upregulated in 98 cases of laryngeal carcinoma tissues. CCL20 and IL-17A may be involved in the progression of laryngeal carcinoma.

3.2. Correlation between Expression Levels of CCL20 and IL-17A in Laryngeal Carcinoma Tissues. Correlation between expression levels of CCL20 and IL-17A in laryngeal carcinoma tissues was analyzed by the Pearson correlation test. A positive correlation between CCL20 and IL-17A in
laryngeal carcinoma, finally, was identified ($r = 0.3245, P = 0.0011$) (Figure 2).

3.3. Diagnostic Potentials of CCL20 and IL-17A in Laryngeal Carcinoma. Differential expressions of CCL20 and IL-17A in laryngeal carcinoma tissues and normal ones indicated their potentials to be diagnostic hallmarks. Here, ROC curves identified diagnostic values of CCL20 (AUC = 0.9719, cutoff value = 4.86, sensitivity = 98.98%, specificity = 87.76%) (Figure 3(a)) and IL-17A (AUC = 0.7965, cutoff value = 3.39, sensitivity = 71.31%, specificity = 71.52%) (Figure 3(b)) in laryngeal carcinoma. Thus, CCL20 and IL-17A were promising diagnostic hallmarks for laryngeal carcinoma.

3.4. Influences of CCL20 and IL-17A on Survival of Laryngeal Carcinoma Patients. Based on the cutoff value of CCL20 in 98 enrolled laryngeal carcinoma patients, they were assigned into high-level and low-level groups. Through collecting 5-year follow-up data of enrolled patients, Kaplan-Meier curves revealed worse survival in laryngeal carcinoma patients of the high-level group compared to those of the low-level group (HR = 13.73, $P < 0.001$) (Figure 4(a)). In a similar way, worse prognosis was observed in laryngeal carcinoma patients expressing high level of IL-17A (HR = 10.45, $P = 0.0012$) (Figure 4(b)). Moreover, overall survival was lower in laryngeal carcinoma patients with both high levels of CCL20 and IL-17A compared with those expressing both low levels (HR = 14.55, $P = 0.0022$) (Figure 4(c)). As a result, CCL20 and IL-17A were unfavorable to the prognosis of laryngeal carcinoma.

4. Discussion

Laryngeal carcinoma is a common malignancy in the regions of ears, throat, and nose. The mortality and incidence of laryngeal carcinoma present increased trends annually [17]. The majority of laryngeal carcinoma patients in the early stage could be recovered or even cured after active treatment. However, most laryngeal carcinoma patients are diagnosed in advanced stage (about 70%) owing to atypical symptoms, leading to poor prognosis and high mortality [18]. Meanwhile, high rates of metastases and recurrence severely restrict clinical outcomes of laryngeal carcinoma as well. The 5-year survival of advanced laryngeal carcinoma is as low as 50% [19].

Human CCL20 locates on chromatin 2q35-36, containing 4 exons and 3 introns [20]. In 1997, Hieshima et al. [21] first found that biological functions of CCL20 are closely linked to one α helix and three β-pleated sheets in its structure. CCL20 is expressed in liver tissue, skin keratinocytes, etc. [22]. CCL20 is of significance in the physiological barrier composition and inflammatory response of the corresponding sites [23]. Studies have shown that CCL20 is highly expressed in hepatocellular carcinoma [24]. In laryngeal carcinoma, CCL20 stimulates tumor cells to proliferate and metastasize [7]. Consistently, our findings uncovered the upregulated CCL20 in laryngeal carcinoma tissues, which was an unfavorable factor for the prognosis. Furthermore, its diagnostic value was identified.

IL-17 is a cytokine mainly secreted by CD4+ T lymphocytes, monocytes, etc. It is critical in natural immunity and host defense, participating in immune regulation and tumor cell growth [25]. As a crucial regulator in immune surveillance, IL-17 triggers angiogenesis and tumor growth in the tumor microenvironment [26]. In many types of tumors, IL-17 is upregulated [27, 28]. IL-17A is a member of the IL-17 family, which is of significance in inflammatory diseases and allergic diseases [29, 30]. Besides, IL-17A is involved in the occurrence and progression of tumors as well [31, 32]. Here, IL-17A was found to be upregulated in laryngeal carcinoma tissues and predicted a poor prognosis.

Wang et al. [17] suggested that CCL20 and IL-17A are effective diagnostic hallmarks for early-stage colorectal carcinoma. High levels of CCL20 and IL-17A predict worse survival in colorectal carcinoma patients, which could be served as independent prognostic factors. Our findings uncovered worse survival in laryngeal carcinoma patients...
expressing both high levels of CCL20 and IL-17A. Based on these data, we believed that synergistic detection of CCL20 and IL-17A levels is effective and sensitive for predicting the prognosis of laryngeal carcinoma.

5. Conclusions

CCL20 and IL-17A are upregulated in laryngeal carcinoma tissues, which are positively correlated and unfavorable to the prognosis of laryngeal carcinoma. CCL20 and IL-17A are promising candidates of laryngeal carcinoma hallmarks.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declared no conflict of interest.

Authors’ Contributions

YT, HH, and HW designed the study and performed the experiments; YLu and XW collected the data; YLi and ZL analyzed the data; YT, HH, and HW prepared the manuscript. All authors read and approved the final manuscript. Yaoshu Teng, Hanyi He, and Hongmei Wang contributed equally to this work.

Acknowledgments

This work was supported by grants from the Zhejiang Provincial Natural Science Foundation of China (No. LGJ22H130001), the Medical and Health Technology Program of Zhejiang (No. 2021RC101 and No. 2019RC065), the Science and Technology Development Project of Hangzhou (No. 20201203B199), and the Medical and Health Technology Program of Hangzhou (No. A20200274).

References

[1] A. Christensen, E. Kristensen, M. H. Therkildsen, L. Specht, J. Reibel, and P. Homoe, “Ten-year retrospective study of head and neck carcinoma in situ: incidence, treatment, and clinical
outcome,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, vol. 116, no. 2, pp. 174–178, 2013.

[2] V. Edelfonti, F. Bravi, W. Garavello et al., “Nutrient-based dietary patterns and laryngeal cancer: evidence from an exploratory factor analysis,” Cancer Epidemiology, Biomarkers & Prevention, vol. 19, no. 1, pp. 18–27, 2010.

[3] Y. H. Zhou, Y. Y. Huang, and M. Ma, “MicroRNA-138 inhibits proliferation and induces apoptosis of laryngeal carcinoma via targeting MAPK6,” European Review for Medical and Pharmacological Sciences, vol. 22, no. 17, pp. 5569–5575, 2018.

[4] A. G. Shuman, K. Larkin, D. Thomas et al., “Patient reflections on decision making for laryngeal cancer treatment,” Otolaryngology and Head and Neck Surgery, vol. 156, no. 2, pp. 299–304, 2017.

[5] G. Han, D. Wu, Y. Yang, Z. Li, J. Zhang, and C. Li, “CrkL mediates CCL20/CCR6-induced EMT in gastric cancer,” Cytokine, vol. 76, no. 2, pp. 163–169, 2015.

[6] A. S. Campbell, D. Albo, T. F. Kimsey, S. L. White, and T. N. Wang, “Macrophage inflammatory protein-3α promotes pancreatic cancer cell invasion,” The Journal of Surgical Research, vol. 123, no. 1, pp. 96–101, 2005.

[7] E. Lu, J. Su, Y. Zhou, C. Zhang, and Y. Wang, “CCL20/CCR6 promotes cell proliferation and metastasis in laryngeal cancer by activating p38 pathway,” Biomedicine & Pharmacotherapy, vol. 85, pp. 486–492, 2017.

[8] S. Krohn, J. F. Nies, S. Kapfer et al., “IL-17C/IL-17 receptor E signaling in CD4⁺ T cells promotes TH17 cell-driven glomerulonephritis,” Journal of the American Society of Nephrology, vol. 29, no. 4, pp. 1210–1222, 2018.

[9] I. Monteleone, F. Pallone, and G. Monteleone, “Th17-related cytokines: new players in the control of chronic intestinal inflammation,” BMC Medicine, vol. 9, no. 1, p. 122, 2011.

[10] W. X. Liu, Z. J. Li, X. L. Niu, Z. Yao, and W. M. Deng, “The role of T helper 17 cells and other IL-17-producing cells in bone resorption and remodeling,” International Reviews of Immunology, vol. 34, no. 4, pp. 332–347, 2015.

[11] M. Normanton and L. C. Marti, “Current data on IL-17 and Th17 cells and implications for graft versus host disease,” Einstein (Sao Paulo), vol. 11, no. 2, pp. 237–246, 2013.

[12] B. Yang, H. Kang, A. Fung, H. Zhao, T. Wang, and D. Ma, “The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis,” Mediators of Inflammation, vol. 2014, Article ID 623759, 12 pages, 2014.

[13] T. Xiang, H. Long, L. He et al., “Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133⁺ cancer stem-like cells in ovarian cancer,” Oncogene, vol. 34, no. 2, pp. 165–176, 2015.

[14] R. H. Prabhala, D. Pelluru, M. Fulciniti et al., “Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma,” Blood, vol. 115, no. 26, pp. 5385–5392, 2010.

[15] S. Sirikanjanapong, B. Lanson, M. Amin, F. Martinuik, H. Kamino, and B. Y. Wang, “Cancer tumor of primary laryngeal mucosal melanoma and invasive squamous cell carcinoma with IL-17A and CD70 gene over-expression,” Head and Neck Pathology, vol. 4, no. 4, pp. 295–299, 2010.

[16] D. Wang, W. Yuan, Y. Wang et al., “Serum CCL20 combined with IL-17A as early diagnostic and prognostic biomarkers for human colorectal cancer,” Journal of Translational Medicine, vol. 17, no. 1, p. 253, 2019.

[17] K. Tangsrirong and T. Jitreetat, “Clinical predictors of laryngeal preservation rate in stage III-IV laryngeal cancer and hypopharyngeal cancer patients treated with organ preservation,” Asian Pacific Journal of Cancer Prevention, vol. 20, no. 7, pp. 2051–2057, 2019.

[18] K. L. Focht, B. Martin-Harris, and H. S. Bonilha, “Stroboscopic parameters reported as voice outcome measures in patients treated for laryngeal cancer: a systematic review,” Journal of Medical Speech-Language Pathology, vol. 21, no. 3, 2013.

[19] D. C. Koestler, J. Li, J. A. Baron et al., “Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon,” Modern Pathology, vol. 27, no. 1, pp. 145–155, 2014.

[20] J. M. Pérez-Cañadillas, Á. Zaballos, J. Gutiérrez et al., “NMR solution structure of murine CCL20/MIP-3α, a chemokine that specifically chemotactically immature dendritic cells and lymphocytes through its highly specific interaction with the β-chemokine receptor CCR6,” The Journal of Biological Chemistry, vol. 276, no. 30, pp. 28372–28379, 2001.

[21] K. Heshima, T. Imai, G. Opdenakker et al., “Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver,” The Journal of Biological Chemistry, vol. 272, no. 9, pp. 5846–5853, 1997.

[22] M. Schmutz, S. Neyer, C. Rainer et al., “Expression of the C-C chemokine MIP-3α/CCL20 in human epidermis with impaired permeability barrier function,” Experimental Dermatology, vol. 11, no. 2, pp. 135–142, 2002.

[23] A. Kasar, O. Ludwiczek, S. Holzmann et al., “Increased expression of CCL20 in human inflammatory bowel disease,” Journal of Clinical Immunology, vol. 24, no. 1, pp. 74–85, 2004.

[24] H. Fuji, Y. Itoh, K. Yamaguchi et al., “Chemokine CCL20 enhances the growth of HuH7 cells via phosphorylation of p44/42 MAPK in vitro,” Biochemical and Biophysical Research Communications, vol. 322, no. 3, pp. 1052–1058, 2004.

[25] V. C. Anipindi, P. Bagri, S. E. Dizzell et al., “IL-17 production by γδ T cells is critical for inducing Th17 responses in the female genital tract and regulated by estradiol and microbiota,” Immunohorizons, vol. 3, no. 7, pp. 317–330, 2019.

[26] M. S. Madhur, S. A. Funt, L. Li et al., “Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 7, pp. 1565–1572, 2011.

[27] C. G. Hurtado, F. Wan, F. Housseau, and C. L. Sears, “Roles for interleukin 17 and adaptive immunity in pathogenesis of colorectal cancer,” Gastroenterology, vol. 155, no. 6, pp. 1706–1715, 2018.

[28] J. P. Alves, T. A. A. D. M. Fernandes, J. M. G. De Araújo et al., “Th17 response in patients with cervical cancer,” Oncology Letters, vol. 16, no. 5, pp. 6215–6227, 2018.

[29] A. De Angulo, R. Faris, B. Daniel, C. Jolly, and L. DeGraef et al., “Age-related increase in IL-17 activates pro-inflammatory signaling in prostate cells,” Prostate, vol. 75, no. 5, pp. 449–462, 2015.

[30] X. Song and Y. Qian, “IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases,” Cellular Signalling, vol. 25, no. 12, pp. 2335–2347, 2013.
[31] M. Numasaki, J. I. Fukushi, M. Ono et al., “Interleukin-17 promotes angiogenesis and tumor growth,” Blood, vol. 101, no. 7, pp. 2620–2627, 2003.

[32] G. Cui, A. Yuan, R. Goll, and J. Florholmen, “IL-17A in the tumor microenvironment of the human colorectal adenoma-carcinoma sequence,” Scandinavian Journal of Gastroenterology, vol. 47, no. 11, pp. 1304–1312, 2012.